Test ID: BCELL B-Cell and Antibody Deficiency Gene Panel, Varies
Ordering Guidance
Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated
Specimen Type: Skin biopsy
Supplies: Fibroblast Biopsy Transport Media (T115)
Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.
Specimen Volume: 4-mm punch
Specimen Stability Information: Refrigerated (preferred)/Ambient
Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.
Specimen Type: Cultured fibroblasts
Container/Tube: T-25 flask
Specimen Volume: 2 Flasks
Collection Instructions: Submit confluent cultured fibroblast cells from a skin biopsy from another laboratory. Cultured cells from a prenatal specimen will not be accepted.
Specimen Stability Information: Ambient (preferred)/Refrigerated (<24 hours)
Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
Useful For
Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of an inherited primary B-cell disorder or humoral immunodeficiency
Establishing a diagnosis of a primary B-cell disorder or humoral immunodeficiency, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved
Identifying variants within genes known to be associated with primary B-cell disorders or humoral immunodeficiencies, allowing for predictive testing of at-risk family members
Genetics Test Information
This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 61 genes associated with inherited B-cell disorders and humoral immunodeficiency: ADA, ADA2, AICDA, ATP6AP1, BLNK, BTK, CARD11, CD19, CD27, CD40, CD40LG, CD70, CD79A, CD79B, CD81, CDCA7, CTLA4, CR2, CXCR4, DCLRE1C, DNMT3B, GATA2, ICOS, IGHM, IGLL1, IKBKG, IKZF1, IKZF3, IL21, IL21R, IRF2BP2, KDM6A, KMT2A, KMT2D, LIG1, LRBA, MOGS, MS4A1, NFKB1, NFKB2, PIK3CD, PIK3R1, PLCG2, PRKCD, RAC2, RAG1, RAG2, RNF168, SEC61A1, SH2D1A, SH3KBP1, SLC39A7, TCF3, TNFRSF13B, TNFRSF13C, TNFSF12, TNFSF13, TOP2B, TRNT1, UNG, and XIAP. See Targeted Genes and Methodology Details for B-Cell and Antibody Deficiency Gene Panel for details regarding the targeted gene regions evaluated by this test.
Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for inherited B-cell disorders and humoral immunodeficiency.
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CULFB | Fibroblast Culture for Genetic Test | Yes | No |
Testing Algorithm
For skin biopsy or cultured fibroblast specimens, fibroblast culture will be performed at an additional charge. If viable cells are not obtained, the client will be notified.
Method Name
Sequence Capture and Amplicon-Based Next-Generation Sequencing (NGS)/Quantitative Real-Time Polymerase Chain Reaction (qPCR) and Sanger Sequencing as needed
Reporting Name
Bcell/Antibody Deficiency GenePanelSpecimen Type
VariesSpecimen Minimum Volume
Blood: 1 mL; Skin biopsy or cultured fibroblasts: See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Clinical Information
Primary B-cell disorders and humoral immunodeficiencies are characterized by an insufficient number of B cells or the impaired functioning or differentiation of B cells. B-cell disorders account for approximately half to two-thirds of all genetic primary immunodeficiency disorders (PIDD). They may result in a decrease or dysfunction of one or more isotypes of immunoglobulin, leading to increased susceptibility to infection, particularly bacterial infections, such as sinopulmonary infections, gastrointestinal infections, otitis, skin infections, and conjunctivitis. In the absence of infection, patients may be asymptomatic and, thus, difficult to diagnose. In addition, primary B-cell disorders may result in lymphoproliferative disorders or be associated with autoimmune (AI) manifestations, including AI cytopenias, AI endocrine disorders, and AI enteropathy.
PIDD that are primarily antibody deficiencies fall into four main categories:
1. Agammaglobulinemias, which are characterized by severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells
2. Common variable immunodeficiency (CVID)-like diseases that are characterized by severe reduction in at least two serum immunoglobulin isotypes with normal or low number of B cells
3. Hyper-IgM syndromes, which are characterized by severe reduction in serum IgG and IgA with normal or elevated IgM and normal numbers of B cells
4. A mixed group of isotype, light chain, or functional antibody deficiencies generally with normal numbers of B cells
In addition, there are several PIDD that also have an associated T-cell or other cellular immunodeficiency as well as B-cell defects.
Agammaglobulinemia typically presents in the first few years of life with recurrent bacterial infections, a severe life-threatening bacterial infection (ie, meningitis, sepsis), and decreased lymphoid tissue (ie, small adenoids, tonsils, and lymph nodes in X-linked agammaglobulinemia, due to Bruton tyrosine kinase [BTK] gene variants). Inheritance can be either X-linked (eg, due to variants in BTK), autosomal dominant (eg, TCF3, TOP2B), or autosomal recessive (eg, IGHM, CD79A, CD79B, IGLL1, BLNK, and PIK3R1).
Common variable immunodeficiency (CVID) is the most common adult humoral immunodeficiency disorder with an incidence of approximately 1:10,000 to 1:50,000. CVID may present with frequent and unusual infections during early childhood, adolescence, or adulthood. As per current diagnostic criteria, CVID is not considered in children younger than 4 years of age. In addition, a significant proportion of patients may have autoimmune or inflammatory manifestations, enlarged lymphoid tissues, granulomas, and an increased susceptibility to cancer. These patients typically have normal numbers of B cells (<5% of CVID patients have <1% B cells, which is due to early B-cell defects) but have impaired terminal differentiation, resulting in decreased levels of IgG and IgA, with or without a decrease in IgM. Over two-thirds of patients have quantitative defects in switched memory B cells. Some patients may also have quantitative and functional T-cell defects or natural killer (NK) cell deficiency. Patients with decreased naive T-cell numbers are considered to have late-onset combined immunodeficiency. Genetic variants have been identified in several genes, including ICOS, TNFRSF13B (TACI), CD19, TNFRSF13C (BAFFR), MS4A1 (CD20), CR2 (CD21), CD81, LRBA, NFKB2, and IKZF1 (IKAROS) in a subset of CVID patients. However, most of these patients have unknown genetic defects and may have oligogenic or polygenic causes of disease.
Hyper IgM syndrome is characterized by an inability to switch from the production of IgM-type antibodies to IgG, IgA, or IgE isotypes. The condition is most often caused by variants in CD40LG, but variants in other genes (eg, CD40, AICDA, PI3KCD, UNG) have also been reported to cause disease. Patients with CD40L and CD40 deficiency tend to present with severe opportunistic infections more reminiscent of a cellular immunodeficiency and, therefore, may also be considered as combined immunodeficiencies.
Selective antibody deficiencies may occur when a patient is either lacking a specific immunoglobulin isotype (eg, selective IgA deficiency or IgG deficiency) or a specific vaccine antibody response (impaired pneumococcal polysaccharide responsiveness). Selective deficiencies may be due to variants in genes encoding immunoglobulin heavy or light chains. Selective IgA deficiency (sIgAD) is the most common PIDD with an incidence of 1:200 to 1:1000, depending on the cohort studied. Most patients with sIgAD are asymptomatic though some may have frequent infections. There is also a higher incidence of celiac disease in this group. Most patients with selective antibody deficiencies are treated if they have frequent infections in addition to impaired vaccine antibody responses. Some patients with sIgAD may have autoantibodies to IgA.
Reference Values
An interpretive report will be provided.
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Clinical Reference
1. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424
2. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473-1507. doi:10.1007/s10875-022-01289-3
3. Smith T, Cunningham-Rundles C. Primary B-cell immunodeficiencies. Hum Immunol. 2019;80(6):351-362. doi:10.1016/j.humimm.2018.10.015
4. Peng XP, Caballero-Oteyza A, Grimbacher B. Common variable immunodeficiency: more pathways than roads to Rome. Annu Rev Pathol. 2023;18:283-310. doi:10.1146/annurev-pathmechdis-031521-024229
5. Wang LA, Abbott JK. "Common variable immunodeficiency: Challenges for diagnosis". J Immunol Methods. 2022;509:113342. doi:10.1016/j.jim.2022.113342
6. Ramirez NJ, Posadas-Cantera S, Caballero-Oteyza A, Camacho-Ordonez N, Grimbacher B. There is no gene for CVID - novel monogenetic causes for primary antibody deficiency. Curr Opin Immunol. 2021;72:176-185. doi:10.1016/j.coi.2021.05.010
7. Cardenas-Morales M, Hernandez-Trujillo VP. Agammaglobulinemia: from X-linked to autosomal forms of disease. Clin Rev Allergy Immunol. 2022;63(1):22-35. doi:10.1007/s12016-021-08870-5
8. Jhamnani RD, Nunes-Santos CJ, Bergerson J, Rosenzweig SD. Class-switch recombination (CSR)/dyper-IgM (HIGM) syndromes and phosphoinositide 3-kinase (PI3K) defects. Front Immunol. 2018;9:2172. doi:10.3389/fimmu.2018.02172
9. de la Morena MT. Clinical phenotypes of hyper-IgM syndromes. J Allergy Clin Immunol Pract. 2016;4(6):1023-1036. doi:10.1016/j.jaip.2016.09.013
10. Yazdani R, Fekrvand S, Shahkarami S, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clin Immunol. 2019;198:19-30. doi:10.1016/j.clim.2018.11.007
11. Bousfiha A, Moundir A, Tangye SG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508-1520. doi:10.1007/s10875-022-01352-z
Day(s) Performed
Varies
Report Available
28 to 42 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81443
88233-Tissue culture, skin, solid tissue biopsy (if appropriate)
88240-Cryopreservation (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
BCELL | Bcell/Antibody Deficiency GenePanel | 97565-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
620107 | Test Description | 62364-5 |
620108 | Specimen | 31208-2 |
620109 | Source | 31208-2 |
620110 | Result Summary | 50397-9 |
620111 | Result | 82939-0 |
620112 | Interpretation | 69047-9 |
620113 | Additional Results | 82939-0 |
620114 | Resources | 99622-3 |
620115 | Additional Information | 48767-8 |
620116 | Method | 85069-3 |
620117 | Genes Analyzed | 82939-0 |
620118 | Disclaimer | 62364-5 |
620119 | Released By | 18771-6 |
mcl-moltechtestmenu